Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 7/20 | 0.66 |
| ▸ | BCL9 | O00512 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17080678 | 0.84 | MGLL (0.46) | MGLLBCL9CTNNB1GAAFAAH | |
| SCHEMBL21634482 | 0.83 | MGLL (0.80) | MGLLBCL9CTNNB1 | |
| SCHEMBL17080654 | 0.82 | MGLL (0.76) | MGLLBCL9CTNNB1GAAKCNH2 | |
| SCHEMBL1400533 | 0.81 | MGLL (1.00) | MGLLBCL9CTNNB1 | |
| SCHEMBL18359784 | 0.80 | MGLL (0.75) | MGLLBCL9CTNNB1FAAHTRPV1 | |
| SCHEMBL1389312 | 0.80 | MGLL (0.75) | MGLLBCL9CTNNB1FAAHTRPV1 | |
| SCHEMBL2773144 | 0.79 | MGLL (0.97) | MGLLBCL9CTNNB1FAAHTRPV1 | |
| SCHEMBL14907653 | 0.79 | MGLL (0.72) | MGLLBCL9CTNNB1GAAFAAH | |
| SCHEMBL14907652 | 0.78 | MGLL (0.67) | MGLLBCL9CTNNB1GAAFAAH | |
| SCHEMBL16139295 | 0.78 | MGLL (1.00) | MGLLBCL9CTNNB1FAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381284-A1 | Controlled-Release PTH Compound | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2023-11-30 | — | — | US | disclosed |
| US-11793861-B2 | PTH prodrugs | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2023-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793861-B2 | PTH prodrugs | PTH1R, PTMS, PHPT1 | MGLL 3418/4885BCL9 3499/4885CTNNB1 2490/4885 |
| US-20230381284-A1 | Controlled-Release PTH Compound | PTH1R, CALCA, CALCB | MGLL 2938/4885BCL9 2506/4885CTNNB1 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.